Profile | GDS2987 / GI_23308723-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 21.7 | 57 |
GSM215244 | HMVEC_vehicle_rep2 | 49.5 | 68 |
GSM215253 | HMVEC_vehicle_rep3 | 57.1 | 72 |
GSM215254 | HMVEC_atorvastatin_rep1 | 59.6 | 71 |
GSM215282 | HMVEC_atorvastatin_rep3 | 31.8 | 57 |
GSM215344 | HMVEC_atorvastatin_rep2 | 38.5 | 63 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 30 | 50 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 17.3 | 34 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 47.6 | 60 |
GSM215294 | HMVEC_SLx2119_rep1 | 61.9 | 73 |
GSM215295 | HMVEC_SLx2119_rep2 | 57.1 | 68 |
GSM215296 | HMVEC_SLx2119_rep3 | 42.3 | 56 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 28.2 | 41 |
GSM215310 | PASMC_vehicle_rep3 | 9.1 | 15 |
GSM215311 | PASMC_atorvastatin_rep1 | 22 | 37 |
GSM215312 | PASMC_atorvastatin_rep2 | 30.6 | 44 |
GSM215313 | PASMC_atorvastatin_rep3 | 32.2 | 43 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 5.1 | 10 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 20 | 33 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 6.1 | 12 |
GSM215329 | PASMC_SLx2119_rep3 | 16.3 | 31 |
GSM215330 | Fibroblasts_vehicle_rep1 | 11.8 | 28 |
GSM215331 | Fibroblasts_vehicle_rep2 | 18.7 | 46 |
GSM215332 | Fibroblasts_vehicle_rep3 | 10.1 | 33 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 2.3 | 6 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 8.1 | 23 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 0.6 | 1 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 23.2 | 57 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 20.4 | 53 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 21.8 | 51 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 17.8 | 46 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 18.4 | 42 |